NCT04957758: A trial that was reported late by Oyster Point Pharma, Inc.
This trial has reported, although it was 41 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04957758 |
|---|---|
| Title | A Phase 2, Multicenter, Randomized, Controlled, Double-Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray in Subjects With Neurotrophic Keratopathy (the Olympia Study) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 17, 2021 |
| Completion date | Jan. 27, 2023 |
| Required reporting date | Jan. 27, 2024, midnight |
| Actual reporting date | March 8, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 41 |